Curigliano Valentina, Giovinale Maria, Fonnesu Claudia, Cerquaglia Claudia, Verrecchia Elena, Turco Simona, Manganelli Chiara, Manna Raffaele
Department of Internal Medicine, Catholic University of the Sacred Heart, Largo Gemelli, 8-00168, Rome, Italy.
Clin Rheumatol. 2008 Jul;27(7):933-6. doi: 10.1007/s10067-008-0857-5. Epub 2008 Mar 11.
Behçet's disease is a systemic inflammatory disorder without a specific treatment that is chosen on the basis of the type and severity of manifestation in the organ involved. More recently, biological agents like etanercept have emerged as possible therapeutic alternatives in patients resistant to conventional therapy. We describe the successful treatment for 1 year of resistant Behçet's disease with etanercept. After the administration of this drug, a resolution of the clinical, laboratory and instrumental picture was achieved with a suspension of immunosuppressive treatments and a reduction of steroid dependency (5 mg/day). No side effects were observed.
白塞病是一种全身性炎症性疾病,尚无基于受累器官表现类型和严重程度选择的特异性治疗方法。最近,像依那西普这样的生物制剂已成为对传统治疗耐药患者可能的治疗选择。我们描述了用依那西普成功治疗耐药性白塞病1年的情况。使用这种药物后,临床、实验室和影像学表现得到缓解,免疫抑制治疗暂停,类固醇依赖性降低(5毫克/天)。未观察到副作用。